Role of calcium and vitamin d in prevention of postmenopausal osteoporosis in patients with endometriosis

In: Reproductive Endocrinology · 2015 · vol. 0(22) , pp. 70 · doi:10.18370/2309-4117.2015.22.70-75 · W1851987416
article OA: diamond CC0
AI-generated summary by claude@2026-06, 2026-06-08

Calcium-D3 Nycomed slowed or stopped bone loss in postmenopausal women with endometriosis and calcium deficiency, suggesting its use for osteopenia prevention.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-12 · read from full text

The study assessed the effectiveness of Calcium-D3 Nycomed for prevention and correction of calcium-phosphorus and bone metabolism disorders in 67 endometriosis patients experiencing climacteric syndrome and calcium deficiency, using 35 patients as a treatment group and 32 as a control group without calcium supplementation. Over a 3-month observation period, the main finding was that Calcium-D3 Nycomed slowed or stopped bone loss associated with hypocalcemia in the climacteric context. The authors’ caveat is that follow-up lasted only 3 months, limiting conclusions about longer-term outcomes. Relevance to endometriosis: the paper focuses on calcium and vitamin D prevention of postmenopausal osteoporosis specifically in patients with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

The study to assess the effectiveness of the use of the drug Calcium-D3 Nycomed for the prevention and correction of disorders of calcium-phosphorus metabolism, bone metabolism in 67 patients with endometriosis on the background of climacteric syndrome and calcium deficiency was performed. 35 patients (main group) against the symptomatic treatment of climacteric syndrome were prescribed Calcium-D3 Nycomed. 32 patients, who did not receive calcium supplements, entered the control group. The period of observation in the course of treatment was 3 months.The most important result of the treatment was slowing or stopping bone loss resulting from the use of Calcium-Dз Nycomed. It is possible to recommend the use of this drug in patients with endometriosis and symptoms of hypocalcemia on the background of climacteric syndrome for the prevention and treatment of osteopenic syndrome
Full text 3,894 characters · extracted from oa-doi-fallback · click to expand
Role of calcium and vitamin d in prevention of postmenopausal osteoporosis in patients with endometriosis DOI: https://doi.org/10.18370/2309-4117.2015.22.70-75Keywords: endometriosis, menopause, osteoporosis, vitamin D, Calcium-D3 NycomedAbstract The study to assess the effectiveness of the use of the drug Calcium-D3 Nycomed for the prevention and correction of disorders of calcium-phosphorus metabolism, bone metabolism in 67 patients with endometriosis on the background of climacteric syndrome and calcium deficiency was performed. 35 patients (main group) against the symptomatic treatment of climacteric syndrome were prescribed Calcium-D3 Nycomed. 32 patients, who did not receive calcium supplements, entered the control group. The period of observation in the course of treatment was 3 months. The most important result of the treatment was slowing or stopping bone loss resulting from the use of Calcium-Dз Nycomed. It is possible to recommend the use of this drug in patients with endometriosis and symptoms of hypocalcemia on the background of climacteric syndrome for the prevention and treatment of osteopenic syndrome References - Adamyan, L.V. Genetic aspects of gynecological diseases. Moscow. GEOTAR -Media (2008): 164–168. - Baran, D.T., Faulkner, K.G., Genant, H.K., Miller, P.D. “Diagnostics and treatment of osteoporosis: the principles of the bone densitometry use.” Osteoporosis and osteopathy, 3(1998): 10–15. - Zakharenko, N.F., Tatarchuk, T.F., Kovalenko, N.V. “The role of oxidative stress in the genesis of endometriosis.” Reproductive Endocrinology, 4(18) (2014): 13–16. - Medical and demographic atlas of Ukraine. Ukraine in the European context, the main causes of mortality. Issue 14 / V.P. Voitenko, A.V. Pisaruk, N.M. Koshel, M.G. Akhaladze. Kyiv. Fenix (2012): 62 p. - Smetnik, V.P., Yureneva, S.V. “Postmenopausal osteoporosis.” Difficult Patient, 6 (Vol. 2) (2004): 27–33. - Toroptseva, N.V. “Prevention of postmenopausal osteoporosis: the role of calcium and vitamin D.” Gynecology, 5–6 (Vol. 7) (2006): 52–55. - Body, J.J., et al. “Vitamin D with calcium reduces mortality: patient level pooled analysis of 70.528 patient fromeight major vitamin D trials.” Osteoporos Int, 23(Suppl. 1) (2012): 1–23. - R ejnmark, L., Aveneil, A., Masud, T., et al. “Vitamin D with Calcium Reduces Mortality: Patient Level Pooled Analysis of 70,528 Patients from Eight Major Vitamin D Trials.” J Clin Endocrin Metab, (2012): 1–12. - Buyalos, R.P., et al. “Endometriosis-associated infertility.” Curr Opin Obstet Gynecol, 12(2000): 377–381. - C urhan, G.C., Willett, W.C., et al. “Dietary factors and the risk of incident kidney stones in younger women: Nurses’ Health Study ІІ.” Arch Intern Med, 164(8) (2004): 885–891. - Hummelshoj, L. “Medical needs in endometriosis.” Gynaecology Forum, 15(2) (2010): 5–7. - N eukomm, C., et al. “Die Endometriose – eine wenig bekannte, oft unerkannte Frauenkrankheit.” Schweiz Med Forum, 8(30–31) (2008): 539–543. - C occia, M.E., et al. Hum Reprod, 11(2011): 3000–3007. Downloads Published How to Cite Issue Section License Copyright (c) 2015 Н. Ф. Захаренко, Н. В. Коваленко, В. П. Ковбасий This work is licensed under a Creative Commons Attribution 4.0 International License. Authors who publish with this journal agree to the following terms: - Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (7)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK